Key result
The ACE I/D polymorphism was significantly associated with an increased risk of diabetic nephropathy in patients with type 2 diabetes, with DD/ID genotype carriers having a 1.54 times higher risk compared to II genotype carriers (OR 1.54).
Why the study?
The renin-angiotensin-aldosterone system plays a major role in diabetic nephropathy, motivating evidence synthesis on the association between ACE gene insertion/deletion polymorphism and diabetic nephropathy risk.
Does the ACE gene I/D polymorphism increase the risk of diabetic nephropathy in patients with type 2 diabetes?
Meta-Analysis (n=8,616)
Does the ACE gene I/D polymorphism increase the risk of diabetic nephropathy in patients with type 2 diabetes?
Odds Ratio: 1.54 (95% CI 1.31–1.81)
p-value: p=<0.001
The ACE I/D polymorphism, specifically the presence of the D allele, is significantly associated with an increased risk of developing diabetic nephropathy in patients with type 2 diabetes.
May support genetic risk stratification in type 2 diabetes; confirms ACE I/D polymorphism association with diabetic nephropathy.
Introduction: Diabetic nephropathy (DN) is a progressive renal disease characterized by persistent albuminuria that leads to end-stage renal disease in both type 1 diabetes (T1DM) and type 2 diabetes (T2DM) patients. The renin-angiotensin-aldosterone system (RAAS) plays a major role in the onset and progression of DN. Objectives: The present meta-analysis is intended to synthesize evidence on the association between ACE gene insertion and deletion (ACE I/D) polymorphism and the risk of DN. Methods: PubMed, Scopus, Google Scholar and Embase were searched to retrieve relevant publications. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the association between ACE I/D polymorphism and DN risk. The Cochrane Q test and I2 statistic were used to detect heterogeneity. To assess between-study heterogeneity, subgroup analysis and sensitivity analysis were performed. Funnel plots and Egger’s test were used to estimate publication bias. Results: Around 45 articles (47 studies) with 6124 patients of DN and 2492 T2DM patients (controls) were ultimately considered for meta-analysis. Overall, the ACE I/D polymorphism was associated with DN under three different genetic models (allelic model: OR = 1.34; 95% CI: 1.20- 1.49; P<0.001; dominant model: OR= 1.54; 95% CI: 1.31- 1.81; P<0.001; and recessive model: OR= 1.39; 95% CI: 1.19- 1.63; P<0.001). Significant heterogeneity (I2 > 50%) was present in the analysis for all ethnic groups. Further, there is no evidence for publication bias in this meta-analysis. Conclusion: The current meta-analysis provided confirmation that the ACE I/D polymorphism is correlated with an increased risk of DN in patients with T2DM and the D allele of ACE I/D was a susceptible factor.
No takes yet. Share an insight, caveat, or question.
Bhaskar et al. (2019) conducted a meta-analysis in Diabetic nephropathy in Type 2 Diabetes (n=8,616). ACE gene I/D polymorphism (DD/ID genotypes) vs. ACE II genotype was evaluated on Risk of diabetic nephropathy (OR 1.54, 95% CI 1.31-1.81, p=<0.001). The ACE I/D polymorphism was significantly associated with an increased risk of diabetic nephropathy in patients with type 2 diabetes, with DD/ID genotype carriers having a 1.54 times higher risk compared to II genotype carriers (OR 1.54).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: